Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Integra Lifesciences (IART) and lowers the price target from $46 to $41.

March 01, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Integra Lifesciences and lowers the price target from $46 to $41.
The reduction in the price target by Truist Securities suggests a less optimistic outlook on the stock's future performance, which could lead to a negative short-term impact on its price. The Hold rating indicates that the analyst does not see significant upside or downside from the current level, but the lowered target price points to potential concerns about the company's valuation or growth prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100